FDA approves Zolgensma, the first gene replacement therapy for SMA
The gene therapy drug Zolgensma (AVXS-101) receives FDA approval to treat spinal muscular atrophy in children below 24 months.
Category: Updates
FDA approves Zolgensma, the first gene replacement therapy for SMA
The gene therapy drug Zolgensma (AVXS-101) receives FDA approval to treat spinal muscular atrophy in children below 24 months.
Gene therapy works wonders in children with SMA type 2
AveXis presented data that shows astonishing efficacy of AVXS-101 in SMA type 2 children
Gene therapy works wonders in children with SMA type 2
AveXis presented data that shows astonishing efficacy of AVXS-101 in SMA type 2 children
Questions and answers about Spinraza in the UK
TreatSMA anwers the most common questions regarding access to Spinraza treatment
Questions and answers about Spinraza in the UK
TreatSMA anwers the most common questions regarding access to Spinraza treatment
Press release on NICE decision to recommend Spinraza treatment
Our official press release on NICE decision to recommend Spinraza
Press release on NICE decision to recommend Spinraza treatment
Our official press release on NICE decision to recommend Spinraza